16 research outputs found
The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study
The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study
Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals
Deficient BH4 production via de novo and salvage pathways regulates NO responses to cytokines in adult cardiac myocytes
Adult rat cardiac myocytes typically display a phenotypic response to cytokines manifested by low or no increases in nitric oxide (NO) production via inducible NO synthase (iNOS) that distinguishes them from other cell types. To better characterize this response, we examined the expression of tetrahydrobiopterin (BH4)-synthesizing and arginine-utilizing genes in cytokine-stimulated adult cardiac myocytes. Intracellular BH4 and 7,8-dihydrobiopterin (BH2) and NO production were quantified. Cytokines induced GTP cyclohydrolase and its feedback regulatory protein but with deficient levels of BH4 synthesis. Despite the induction of iNOS protein, cytokine-stimulated adult cardiac myocytes produced little or no increase in NO versus unstimulated cells. Western blot analysis under nonreducing conditions revealed the presence of iNOS monomers. Supplementation with sepiapterin (a precursor of BH4) increased BH4 as well as BH2, but this did not enhance NO levels or eliminate iNOS monomers. Similar findings were confirmed in vivo after treatment of rat cardiac allograft recipients with sepiapterin. It was found that expression of dihydrofolate reductase, required for full activity of the salvage pathway, was not detected in adult cardiac myocytes. Thus, adult cardiac myocytes have a limited capacity to synthesize BH4 after cytokine stimulation. The mechanisms involve posttranslational factors impairing de novo and salvage pathways. These conditions are unable to support active iNOS protein dimers necessary for NO production. These findings raise significant new questions about the prevailing understanding of how cytokines, via iNOS, cause cardiac dysfunction and injury in vivo during cardiac inflammatory disease states since cardiac myocytes are not a major source of high NO production
Developmental susceptibility of neurons to transient tetrahydrobiopterin insufficiency and antenatal hypoxia–ischemia in fetal rabbits
Nitric oxide formation in acutely rejecting cardiac allografts correlates with GTP cyclohydrolase I activity
Inducible nitric oxide synthase (iNOS) is a prominent component of the complex array of mediators in acute graft rejection. While NO production is determined by iNOS expression, BH(4) (tetrahydrobiopterin), a cofactor of iNOS synthesized by GTP cyclohydrolase I, has been considered critical in sustaining NO production. In the present study, we examined time-dependent changes in iNOS and GTP cyclohydrolase I in rat cardiac allografts. The increase in iNOS protein and mRNA in allografts was similar at POD4 (post-operative day 4) and POD6. However, the peak increase in intragraft NO level at POD4 was not sustained at POD6. This disparity could not be explained by any decrease in iNOS enzyme activity measured ex vivo with optimal amounts of substrate and cofactors. Lower iNOS activity could be explained by changes in total biopterin levels in allografts at POD4 that was decreased to baseline at POD6. Changes in biopterin production correlated with lower GTP cyclohydrolase I protein levels but not by any change in GTP cyclohydrolase I mRNA. Functionally, allografts displayed bradycardia and distended diastolic and systolic dimensions at POD6 but not at POD4. Likewise, histological rejection scores were increased at POD4 but with a secondary increased stage at POD6. It is hypothesized that the dissimilar amounts of NO at early and later stages of rejection is due to uncoupling of iNOS arising from disproportionate synthesis of BH(4). These findings provide insight into a potential pathway regulating NO bioactivity in graft rejection. Such knowledge may potentially assist in the design of newer strategies to prevent acute graft rejection
Sepiapterin Decreases Acute Rejection and Apoptosis in Cardiac Transplants Independently of Changes in Nitric Oxide and Inducible Nitric-Oxide Synthase Dimerization
Tetrahydrobiopterin (BH4), a cofactor of inducible nitric-oxide
synthase (iNOS), is an important post-translational regulator of NO
bioactivity. We examined whether treatment of cardiac allograft recipients
with sepiapterin
[S-(-)-2-amino-7,8-dihydro-6-(2-hydroxy-1-oxopropyl)-4-(1H)-pteridinone],
a precursor of BH4, inhibited acute rejection and apoptosis in
cardiac transplants. Heterotopic cardiac transplantation was performed in
Wistar-Furth donor to Lewis recipient strain rats. Recipients were treated
daily after transplantation with 10 mg/kg sepiapterin. Grafts were harvested
on post-transplant day 6 for analysis of BH4 (high-performance
liquid chromatography), expression of inflammatory cytokines (reverse
transcription- and real-time polymerase chain reaction), iNOS (Western blots),
and NO (Griess reaction and NO analyzer). Histological rejection grade was
scored, and graft function was determined by echocardiography. Apoptosis,
protein nitration, and oxidative stress were determined by
immunohistochemistry. Treatment of allografts with sepiapterin increased
cardiac BH4 levels by 3-fold without changing protein levels of GTP
cyclohydrolase, the enzyme that regulates de novo BH4 synthesis.
Sepiapterin decreased inflammatory cell infiltrate and significantly inhibited
histological rejection scores and apoptosis similar in magnitude to
cyclosporine. Sepiapterin also decreased nitrative and oxidative stress.
Sepiapterin caused a smaller increase in left ventricular mass versus
untreated allografts but without improving fractional shortening. Sepiapterin
did not alter tumor necrosis factor-α and interferon-γ expression,
whereas it decreased interleukin (IL)-2 expression. Sepiapterin did not change
total iNOS protein or monomer levels, or plasma and tissue NO metabolites
levels. It is concluded that the mechanism(s) of antirejection are due in part
to decreased apoptosis, protein nitration, and oxidation of cardiomyocytes,
which seems to be mediated at the immune level by limiting inflammatory cell
infiltration via decreased IL-2-mediated T-lymphocyte expansion